RCS - Directa Plus PLC - Successful Absorption Evaluation Test

Directa PlusAnnouncement

09/03/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210309:nRSI5527Ra&default-theme=true

RNS Number : 5527R  Directa Plus PLC  09 March 2021

This is an Reach announcement and the information contained is not considered
to be material or to have a significant impact on management's expectations of
the Company's performance. Reach is an investor communication service aimed at
assisting listed and unlisted (including AIM quoted) companies to distribute
non-regulatory news releases into the public domain. Information required to
be notified under the AIM Rules for Companies, Market Abuse Regulation or
other regulation would be disseminated as an RNS regulatory announcement and
not on Reach.

 

9 March 2021

 

Directa Plus plc

("Directa Plus" or the "Company")

 

Successful Absorption Evaluation Test

 

Study finds zero absorption of G+® graphene, underlining safety for textile
applications

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene
nanoplatelets based products for use in consumer and industrial markets, is
pleased to announce that it has received another positive test result relating
to the potential for absorption of the Company's pristine graphene
nanoplatelets powder (Pure G+®) through human skin.  This latest in vitro
test showed that there is no absorption potential for Pure G+®, taking the
total number of positive in vitro test results to eight.

 

The study was carried out by an independent third party and followed the
standards of OECD 428 ("In vitro evaluation of the absorption potential of a
product throughout reconstructed human epidermis").  The purpose of the test
was the evaluation of the skin absorption potential of Pure G+® through an in
vitro reconstructed human epidermis.  Pure G+ was applied on the tissue
surface for six and 24 hours and at the end of the experimental time, a
calculation of the quantity of Pure G+® graphene that had penetrated through
the epidermis was performed.

 

The acquisition of further successful results from in vitro tests of the
Company's hypoallergenic, non-toxic products is vital for their use in textile
markets where customers have to be certain of the safety of the apparel they
produce and market.

 

Directa Plus has continued to launch its own branded clothing collections with
the latest available at:

https://graphene-plus.com/cosmic-collection/
(https://graphene-plus.com/cosmic-collection/)

 

Giulio Cesareo, Chief Executive of Directa Plus, commented: "Our suite of
successful in vitro tests proves to customers in the textile industry that
they can safely adopt our products to create exciting new garments enhanced by
our graphene products.  We will continue to ensure that our products are
tested to the highest possible standards before releasing them to our target
markets, in keeping with our core values."

 

For further information please visit http://www.directa-plus.com/
(http://www.directa-plus.com/) or contact:

 

 Directa Plus plc                                            +39 02 36714458
 Giulio Cesareo, CEO
 Marco Ferrari, CFO
 Cenkos Securities plc (Nominated Adviser and Joint Broker)  +44 131 220 6939
 Neil McDonald / Pete Lynch
 N+1 Singer (Joint Broker)                                   +44 20 7496 3069
 Rick Thompson / Phil Davies
 Tavistock (Financial PR and IR)                             +44 20 7920 3150
 Simon Hudson / Edward Lee

 

About Directa Plus

Our focus is principally on the two sectors in which we have strong commercial
advantage through developed and launched products and a technological lead:
environmental (based on our Grafysorber® product) and textiles (based on our
G+ products).  In addition, we will continue to pursue opportunities in
elastomers and composites (including tyres and asphalt), also using our G+
products.  All our products are hypoallergenic, non-toxic and sustainably
produced.

 

-ends-

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASSSFAAEFSEFD